Utama › Kanser Paru-paru › New York › New York City
Kajian klinikal Kanser Paru-paru di New York City, NY
60 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar New York City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of ZW251 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mental Health Care in People With Cancer
Mengambil peserta
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Mengambil pesertaFasa 3
- Mount Sinai Chelsea, New York
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Mengambil pesertaFasa 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Empathic Communication Skills (ECS) Training
Mengambil pesertaSukarelawan sihat dialu-alukan
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 2
- Memorial Sloan Kettering Hospital, New York
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Mengambil pesertaFasa 3
- NYU Langone's Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Mengambil pesertaFasa 3
- Memorial Sloan Kettering Cancer Center, New York
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Mengambil pesertaFasa 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center, New York
A Registry for People With Lung Cancer
Mengambil pesertaKajian pemerhatian
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Mengambil pesertaFasa 2/3
- NYU Langone Health, New York
- Weill Cornell Medical College, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Mengambil pesertaFasa 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Mengambil pesertaFasa 1/2
- NYU Langone Health Perlmutter Cancer Center, New York
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Mengambil pesertaFasa 1/2
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Mengambil pesertaFasa 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Mengambil pesertaFasa 1/2
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Memorial Sloan Kettering Cancer Center, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Mengambil pesertaFasa 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Laura and Isaac Perlmutter Cancer Center, New York
- Manhattan Eye, Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Mengambil pesertaFasa 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Mengambil pesertaFasa 1/2
- Avenzo Therapeutics Recruiting Site, New York
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Mengambil pesertaFasa 1
- Perlmutter Cancer Center - NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Mengambil pesertaFasa 3
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Mengambil pesertaFasa 3
- Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Mengambil pesertaFasa 1
- New York Cancer & Blood Specialists, New York
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- New York Proton Center, New York
- Manhattan Eye Ear and Throat Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
- dan 1 lagi
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Mengambil pesertaFasa 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- New York Proton Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Lung Cancer Risk
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Mengambil pesertaFasa 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Study of a Side Effects and Resource Navigation Program for People With Cancer
Mengambil peserta
- City College of New York (Data Collection AND Specimen Analysis), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Mengambil pesertaFasa 1/2
- New York University Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Mengambil pesertaFasa 2
- New York University Langone Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Mengambil pesertaFasa 1/2
- NYU Langone Medical Center, New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Mengambil pesertaFasa 1/2
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Mengambil pesertaFasa 1
- Research Site, New York
- Research Site, New York
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
Mengambil pesertaFasa 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Mengambil pesertaFasa 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Mengambil pesertaFasa 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Mengambil pesertaFasa 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Brodalumab in the Treatment of Immune-Related Adverse Events
Mengambil pesertaFasa 1
- Columbia University Irving Medical Center, New York
Lung Cancer Biomarkers and Screening
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- NYU Cancer Institute at New York University Medical Center, New York
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Mengambil pesertaFasa 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Mengambil pesertaFasa 2
- Weill Cornell Medicine, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Mengambil pesertaFasa 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Confocal Laser Endomicroscopy VERification
Mengambil peserta
- Montefiore Medical Center, New York
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Mengambil pesertaFasa 1
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
Mengambil pesertaKajian pemerhatian
- Manhattan Eye Ear and Throat Hospital, New York
- Lenox Hill Hospital, New York
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Mengambil pesertaFasa 1/2
- Weill Cornell Medicine, Cornell University (site 126), New York
Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer
Mengambil pesertaKajian pemerhatian
- NYU Langone Health, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Mengambil pesertaFasa 1/2
- NYU Langone Health, New York
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
Mengambil pesertaFasa 2
- NYU Langone Health, New York
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
Mengambil pesertaKajian pemerhatian
- Icahn School of Medicine at Mount Sinai, New York
Comprehensive Outcomes for After Cancer Health
Mengambil pesertaSukarelawan sihat dialu-alukan
- Memorial Sloan Kettering Cancer Center, New York
Kajian Kanser Paru-paru di bandar lain
- Houston, TX78 kajian
- Boston, MA62 kajian
- Los Angeles, CA45 kajian
- Arlington, VA41 kajian
- Washington, DC41 kajian
- Chicago, IL41 kajian
- Baltimore, MD40 kajian
- Nashville, TN40 kajian
- St. Louis, MO39 kajian
- Columbus, OH37 kajian
- Philadelphia, PA36 kajian
- Seattle, WA33 kajian
Kajian lain di New York City
- Kanser Payudara136 kajian
- Kanser Paru-paru Bukan Sel Kecil121 kajian
- Kanser (semua jenis)109 kajian
- Kanser Prostat103 kajian
- Kanser Metastatik93 kajian
- Kanser Kolorektal78 kajian
- Kanser Ovari69 kajian
- Mieloma Pelbagai60 kajian
- Kanser Pankreas60 kajian
- Kanser Endometrium52 kajian
- Leukemia Mieloid Akut51 kajian
- Kegagalan Jantung51 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.